Navigating the CMS 14-Day Rule in Biomarker Testing

How can early identification of patient-specific risk factors help optimize patient outcomes and proactively manage toxicity with ADC therapy? In this video, Tajuana Bradley, DNP, FNP-BC, AOCNP, and Abbey Kaler, PA-C, discuss approaches to evaluating baseline risk factors, identifying patients who may be at increased risk for key ADC-related toxicities, and implementing monitoring, multidisciplinary care, and patient education strategies at treatment initiation.

In this sixth installment, Ms Carroll discusses the TRADE study with abemaciclib and emphasizes the importance of individualized patient care, clear communication about dosing goals, and teamwork among healthcare providers to implement dose escalation effectively. This strategy aims to address patient concerns about side effects while ensuring adherence to the full treatment plan.